John Parkinson is the assistant managing editor for Contagion. Prior to joining MJH Life Sciences in 2020, he has covered a variety of fields and markets including diabetes, oncology, ophthalmology, IT, travel, and local news. You can email him at jparkinson@mjhlifesciences.com.
The American College of Physicians (ACP) CEO says it is important for physicians to move away from this traditional approach to transition to an empathetic style of discussion with patients so they can better relate and help those in need get back on track with their health post-COVID and schedule routine tests and immunizations.
With an estimated 30% of Americans living with a tattoo, the federal agency has developed guidance designed to give manufacturers information and resources to prevent potential health issues.
Metformin was shown to decrease the condition by 41%; whereas, ivermectin and fluvoxamine treatment did not see a clinical benefit.
A new retrospective study found non-oxygen-dependent COVID-19 patients were more likely to experience this phenomenon if they were immunocompromised, receiving concomitant corticosteroids, or had comorbidities.
The update includes several different infections, and offers brief descriptions of significant clinical trials, resistance mechanisms, and antimicrobial susceptibility testing methods for each of the pathogens.
The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been working to help people affected by the healthcare associated infection and getting involved with public advocacy including their support of the prospective antibiotic-related law, the Pasteur Act.
The federal lawsuit filed in court looks to stop the government’s plan to negotiate therapy prices.
The federal agency gave Merck the nod to use the company's antiviral as prophylaxis for Cytomegalovirus Disease (CMV), postoperatively.
A new documentary looks at dealing with the condition long-term, and serves as a microcosm for how people suffer through chronic conditions and diseases, and may not get the help they need.
Atea Pharmaceutical’s investigational therapy, bemnifosbuvir, is in a phase 3 trial for the former and phase 2 for the latter.
European medical committee offers favorable opinion for people with all forms of renal impairment including those on dialysis.
A clinician talks about reducing antibiotic treatment duration for urinary tract infections (UTI).
A large study of patients treated in the intensive care unit (ICU) demonstrates common genetic links that point to a potential reason for people progressing to life-threatening forms of the respiratory virus.
An antibiotic development stakeholder believes the current paradigm needs to be changed in order for more antibiotics to get FDA approved and reduce multidrug-resistance.
This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Sulbactam-durlobactam (Xacduro) was developed to treat the troublesome Acinetobacter baumannii pathogen that can be associated with bacterial pneumonia.
The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
Five-year cumulative data from 2 phase 3 studies looked at 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF (Biktarvy).
The National Institute for Health and Care Excellence (NICE) believes National Health Service (NHS) can use bulevirtide as a treatment option.
New therapeutics have been FDA approved as well as real-world studies glean information about their efficacy.
A vaccine developer discusses the benefits of this approach and the development behind them.
The recommendations look to increase usage of the antiviral and decrease the routine use of the recombinant IL-1 inhibitor for COVID-19 treatment.
There is a lot going on in this area in medicine and here is the most up-to-date news on health programs and therapies.
A clinician presents data on this antibiotic for these troublesome infections at the ongoing MAD-ID conference.
Sulbactam-durlobactam is efficacious against carbapenem-resistant infections, and Innoviva is preparing for the antibiotic's PDUFA at the end of this month.
The latest issue of the Morbidity and Mortality Report discusses the cases.
A new study showed an introduction of beneficial microbiota.
Ferring’s Rebyota therapeutic was studied in this population and demonstrated a 79% efficacy.
Ferring’s Rebyota, which was FDA approved late last year, demonstrated a high efficacy and favorable safety profile in the prevention of recurrent Clostridioides difficile.
The Committee for Medicinal Products for Human Use expressed a positive opinion for bulevirtide for treatment of hepatitis D (HDV).
